Oxazepam (Serax)

Anxiolytic - Benzodiazepine

Overview

Oxazepam is a short-to-intermediate-acting benzodiazepine that was first marketed in 1965 under the brand name Serax. It is FDA-approved for the management of anxiety disorders and the treatment of alcohol withdrawal symptoms. Oxazepam is unique among benzodiazepines because it undergoes direct glucuronidation without requiring hepatic oxidation, making it safer in patients with liver disease and elderly populations. It has the slowest onset of action among common benzodiazepines, making it particularly useful for maintaining sleep rather than inducing sleep. Oxazepam is also an active metabolite of diazepam, prazepam, and temazepam, contributing to the therapeutic effects of these medications.

Mechanism of Action

Oxazepam enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding as an allosteric modulator, increasing the number of chloride ions crossing the cell membrane. This binding causes a conformational change in the GABA receptor, increasing its affinity for GABA and resulting in increased frequency of chloride channel opening. The subsequent hyperpolarization of neuronal cell membranes decreases the rate of synaptic firing, producing anxiolytic, anticonvulsant, hypnotic, sedative, and skeletal muscle relaxant effects. Unlike many other benzodiazepines, oxazepam has been shown to suppress cortisol levels, which may contribute to its anxiolytic properties.

Indications

  • Anxiety Disorders: Management of anxiety disorders and short-term relief of symptoms of anxiety.
  • Alcohol Withdrawal: Management of symptoms associated with alcohol withdrawal syndrome.
  • Tension and Agitation: Treatment of tension, agitation, and irritability, particularly in older patients.
  • Sleep Maintenance: Particularly useful for patients who have difficulty staying asleep rather than falling asleep.
  • Anxiety with Depression: Treatment of anxiety symptoms associated with depression.
  • Social Phobia: Management of social anxiety disorder.
  • PTSD: Post-traumatic stress disorder symptoms.
  • Insomnia: Short-term treatment of sleep disorders.
  • Premenstrual Dysphoric Disorder (PMDD): Management of severe premenstrual symptoms.
  • Catatonia: Adjunctive treatment in catatonic states.
  • Irritable Bowel Syndrome: Management of anxiety-related IBS symptoms.

Dosing and Administration

Indication Starting Dose Usual Range Maximum Dose
Anxiety (Mild-Moderate) 10-15 mg TID-QID 30-60 mg/day 120 mg/day
Anxiety (Severe) 15-30 mg TID-QID 45-120 mg/day 120 mg/day
Elderly/Debilitated 10 mg TID 30-45 mg/day 60 mg/day
Alcohol Withdrawal 15-30 mg TID-QID 45-120 mg/day 120 mg/day
Pediatric (6-12 years)* 1 mg/kg/day divided TID Variable Variable

*No FDA approval for pediatric use under 6 years

  • Timing: Can be taken with or without food; typically dosed 3-4 times daily due to intermediate half-life.
  • Onset: Peak plasma levels occur within 1-4 hours; slowest onset among common benzodiazepines.
  • Duration: Use the lowest effective dose for the shortest time possible to minimize dependence risk.
  • Discontinuation: Use a gradual taper to discontinue oxazepam or reduce dosage to prevent withdrawal reactions.
  • Elderly: Start with 10-15 mg three or four times daily; do not exceed 60 mg per day; increased sensitivity to CNS effects.
  • Hepatic Impairment: Safer than other benzodiazepines due to direct glucuronidation without hepatic oxidation; still use with caution.
  • Renal Impairment: Prolonged half-life and increased volume of distribution in renal disease; monitor closely.
  • Pregnancy: Category C - avoid use; may cause fetal harm and neonatal withdrawal.
  • Pediatric: No FDA approval under age 6; limited guidelines for ages 6-12.
Clinical Pearl: Oxazepam is preferred in patients with liver disease because it bypasses hepatic oxidation and is less likely to accumulate compared to other benzodiazepines. This makes it one of the safest benzodiazepines for elderly patients and those with hepatic impairment.

Pharmacokinetics

Parameter Details
Absorption Complete absorption with 92.8% bioavailability; peak levels in 1.7-2.8 hours
Bioavailability 92.8% oral bioavailability
Metabolism Direct glucuronidation via UGT2B15, UGT2B7, and UGT1A9 to inactive metabolites
Half-Life 5-15 hours (average 6-9 hours); prolonged in renal disease
Volume of Distribution 0.6-2.0 L/kg; steady-state: 0.59 L/kg
Clearance 0.9-2.0 mL/min/kg
Excretion Primarily urine as glucuronide metabolite (80%); 21% unchanged in feces
Active Metabolites None - major advantage over other benzodiazepines
Clinical Pearl: Oxazepam is not subject to CYP450 interactions and does not accumulate upon CYP inhibition, making it ideal for patients on multiple medications or those with unpredictable drug metabolism.

Side Effects

  • CNS: Drowsiness (most common), headache, fatigue, dizziness, light-headedness.
  • Cognitive: Memory impairment, confusion, anterograde amnesia.
  • Motor: Ataxia, slurred speech, weakness.
  • Psychiatric: Depression, nervousness, hyper-excitability.
  • Other: Dry mouth, hypersalivation, decreased libido.

The most common side effect is drowsiness, especially when first starting treatment, which usually resolves with dose reduction.

  • Respiratory Depression: Especially with concomitant opioid use; can be fatal.
  • Severe Allergic Reactions: Angioedema, anaphylaxis; discontinue immediately.
  • Paradoxical Reactions: Aggression, agitation, hallucinations, inappropriate behavior.
  • Withdrawal Syndrome: Life-threatening if stopped abruptly; includes seizures, delirium.
  • Suicidal Ideation: Monitor closely for worsening depression and suicidal thoughts.
  • Falls and Fractures: Increased risk in elderly due to sedation and ataxia.
  • Blood Dyscrasias: Rare cases of leukopenia.
Clinical Pearl: Compared to other benzodiazepines, oxazepam caused significantly more work performance problems in clinical trials, making occupational functioning an important monitoring parameter.

Interactions

  • Opioids: FDA black box warning - can cause profound sedation, respiratory depression, coma, and death.
  • CNS Depressants: Alcohol, barbiturates, sedatives - enhanced sedation; avoid alcohol completely.
  • Antihistamines: Diphenhydramine and other CNS-depressant antihistamines increase respiratory depression risk.
  • CYP450 Interactions: Minimal - major advantage as oxazepam is not subject to CYP interactions.
  • Cimetidine: Does not significantly affect oxazepam kinetics, unlike other benzodiazepines.
  • Oral Contraceptives: No significant interaction with low-dose oral contraceptives.
Clinical Pearl: Oxazepam's lack of CYP450 interactions makes it one of the safest benzodiazepines for drug-drug interaction profiles, particularly valuable in elderly patients on multiple medications.

Contraindications and Warnings

  • Hypersensitivity: Known allergy to oxazepam or other benzodiazepines.
  • Mental Illness with Psychosis: Contraindicated in patients with psychotic disorders.
  • Substance Use Disorders: Should not be prescribed to patients with active substance misuse.
  • Severe Respiratory Insufficiency: Risk of further respiratory compromise.
  • Abuse and Dependence: Schedule IV controlled substance; assess abuse risk before and during treatment.
  • Withdrawal Risk: Physical dependence develops; withdrawal can be life-threatening.
  • Elderly Patients: Increased risk of cognitive impairment, falls, and dementia development.
  • Respiratory Disease: Use with caution in patients with respiratory compromise.
  • Pregnancy and Lactation: Crosses placenta; excreted in breast milk; avoid use.
  • Renal Disease: Prolonged elimination; dose adjustment may be needed.

Evidence and Guidelines

  • Anxiety Efficacy: Double-blind trial vs Passiflora extract showed oxazepam had more rapid onset but caused more work performance problems.
  • Pharmacokinetic Studies: Six-subject crossover study established 92.8% bioavailability and complete absorption.
  • Elderly Safety: Age-related studies show minimal effect on clearance compared to other benzodiazepines.
  • Liver Disease Safety: Multiple studies confirm safety advantage in hepatic impairment due to glucuronidation pathway.
  • Anxiety Guidelines: Recommended for short-term use; not first-line due to dependence potential.
  • Alcohol Withdrawal: Included in most alcohol withdrawal protocols due to safety profile.
  • Geriatric Guidelines: Use not recommended due to increased risk of cognitive impairment and falls.
  • Liver Disease: Preferred benzodiazepine in hepatic impairment guidelines.
  • FDA Guidance: Updated boxed warnings emphasize respiratory depression risk with opioids.

Monitoring Parameters

  • Clinical Response: Assess anxiety levels, sleep quality, and functional improvement within 1-2 weeks.
  • Cognitive Function: Monitor for memory impairment, confusion, and cognitive decline, especially in elderly.
  • Respiratory Status: Monitor cardiovascular and respiratory stability, particularly with concomitant CNS depressants.
  • Fall Risk: Assess gait, balance, and coordination, especially in elderly patients.
  • Abuse Potential: Monitor for signs of misuse, dose escalation, or drug-seeking behaviors.
  • Withdrawal Symptoms: Watch for tremor, agitation, anxiety, seizures during dose reduction.
  • Laboratory Monitoring: Periodic CBC, BUN/creatinine, liver function tests as clinically indicated.
  • Work Performance: Monitor occupational functioning as oxazepam may significantly impair work performance.

Patient Education

  • Onset and Duration: Explain slow onset compared to other benzodiazepines; effects may take 1-4 hours.
  • Dosing Schedule: Take exactly as prescribed; typically 3-4 times daily due to shorter half-life.
  • Alcohol Avoidance: Never use with alcohol - can be fatal; dangerous interactions with all CNS depressants.
  • Drowsiness Warning: May cause significant drowsiness; avoid driving or operating machinery until effects are known.
  • Work Performance: May significantly impair work performance; discuss with employer if necessary.
  • Dependence Risk: Can become habit-forming even at prescribed doses; use only as directed.
  • Gradual Discontinuation: Never stop abruptly - must taper gradually to prevent dangerous withdrawal.
  • Fall Prevention: Rise slowly from sitting/lying position; use caution with stairs and uneven surfaces.
  • Memory Effects: May cause memory problems or "blackouts"; keep written reminders if needed.
  • Emergency Situations: Seek immediate help for difficulty breathing, chest pain, or thoughts of self-harm.
  • Storage and Security: Keep in secure location; controlled substance with abuse potential.
  • Pregnancy: Contact physician immediately if pregnancy is suspected; drug can harm developing fetus.